LUPIN - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 4.0
✅ Positive
Lupin is exhibiting strong momentum with a significant increase in PAT compared to the previous quarter, along with a favorable PEG ratio and healthy ROCE. Volume is exceptionally high, indicating substantial buying interest, and the RSI suggests the stock is relatively undervalued.
⚠️ Limitation
The DII holding has decreased slightly, which could signal waning institutional support. Furthermore, while the recent news regarding oncology asset spin-offs is positive, broader market headwinds and sector-specific concerns could still pressure the stock price.
📉 Company Negative News
Analyst views on Trump's generic tariff roadmap suggest potential challenges for Lupin’s business due to increased competition and pricing pressures. The news highlights a risk related to export markets and profitability.
📈 Company Positive News
Lupin has spun out its oncology assets into Kaveri Therapeutics, leading to around 1% gains in the stock price. This strategic move indicates future growth opportunities and investor confidence.
🏭 Industry
The pharmaceutical sector is currently experiencing mixed sentiment due to generic drug pricing pressures and regulatory changes globally. However, companies with strong R&D pipelines and a diversified product portfolio, like Lupin, are generally performing well.
🧾 Conclusion
A buy price of 2415 ₹ would be suitable considering the momentum. An initial exit level at 2430 ₹ (a 0.7% profit target) could be set, with a stop-loss order placed at 2400 ₹ to mitigate potential downside risk. Overall, given the strong volume and positive indicators, Lupin appears to be a promising candidate for intraday trading today.